Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled salbutamol + ipratropium with or without inhaled furosemide in COPD exacerbations
IRCT20240118060726N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of salbutamol, ipratropium bromide and furosemide in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Clinical signs and symptoms of COPD exacerbation, Pulmonary function tests and 1 more. Started Feb 2024; status: completed.
02
Drugs
salbutamolipratropium bromidefurosemide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on IRCT20240118060726N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240118060726N1.